Skip to content

Salt and its effects on endothelial function in patients with type two diabetes

Effect of salt supplementation on sympathetic nervous system activity and endothelial function in people with type two diabetes

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12613000127707
Acronym
NIl
Enrollment
22
Registered
2013-02-01
Start date
2013-08-01
Completion date
2016-08-31
Last updated
2021-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

A high salt diet is associated with an increased risk of hypertension. By contrast, in patients with type 2 diabetes, a low salt diet is associated with an increased risk for cardiovascular and total mortality. As a low salt intake may increase sympathetic nervous system (SNS) activity, we aim to determine baseline SNS activity and endothelial function in patients with diabetes consuming a habitual low salt diet and determine whether salt loading reduces SNS activity and enhances endothelial function.

Interventions

Salt loading (Slow Sodium, NaCl at a dose of 100mmol/24h in 3 divided doses) or placebo to be taken daily for 3 weeks each. Slow release salt capsules manufactured by Thompson’s compounding pharmacy. As this is a cross over study, there will be a three week washout period between both treatment arms.

Sponsors

Dr Elif Ilhan Ekinci, Director of Diabetes
Lead SponsorIndividual

Study design

Allocation
Randomised controlled trial
Intervention model
Crossover
Primary purpose
Treatment
Masking
Blinded (masking used) (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
All
Age
50 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

Blood Pressure <150/80 Body Mass Index matched 2 out of 3 24 hour urine collections <150mmol/24h 35 patients will be recruited into the Type Two Diabetes arm and 35 non-diabetic patients will be recruited into the control arm.

Exclusion criteria

Other active significant medical problems, including clinical autonomic neuropathy

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026